KRISTYN MOWRY: Open Payments
NPI 1760831846 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$886 in 35 payments from 10 companies in 2025. Trend: 2023 $224 · 2024 $1,152 · 2025 $886
Food & beverage: $886
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 6 | $231 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $109 |
| QOL Medical, LLC | 4 | $94 |
| Phathom Pharmaceuticals, Inc. | 5 | $80 |
| Janssen Biotech, Inc. | 3 | $78 |
| Ardelyx, Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $43 |
| ABBVIE INC. | 2 | $42 |
| PFIZER INC. | 1 | $17 |
Products named: REZDIFFRA, XIFAXAN, Sucraid, VOQUEZNA, TREMFYA, ENTYVIO, IBSRELA, SKYRIZI.
Industry payments across CT — which companies pay providers there.
